Core Viewpoint - China National Pharmaceutical Group Modern (国药现代) announced that its wholly-owned subsidiary, China National Pharmaceutical Industry Co., Ltd. (国药工业), has received a GMP compliance inspection notice for its Langfang branch, indicating that the production line for lyophilized powder injection has passed the GMP compliance check [1] Group 1: GMP Compliance Inspection - The GMP compliance inspection scope covered the lyophilized powder injection production line at the Langfang branch of China National Pharmaceutical Industry [1] - The production line is newly built, with a total investment of approximately RMB 92.8277 million (unaudited) [1] - The successful compliance check indicates that the new production line meets the requirements of the "Good Manufacturing Practice for Pharmaceutical Products (2010 Revision)" [1] Group 2: Market Implications - The approval of the lyophilized powder injection production line is expected to help the company stabilize and increase the production capacity of its anesthesia and analgesia product segment to meet market demand [1] - The recent developments are not expected to have a significant impact on the company's current operating performance [1]

Group 1 - The company’s subsidiary, Hangzhou Ausino Biotechnology Co., Ltd., has received a GMP compliance inspection notice from the Zhejiang Provincial Drug Administration, confirming that the active pharmaceutical ingredient (API) of Ograpivir Sodium has passed the GMP compliance check [1] - The inspection took place from January 14 to January 16, 2026, covering specific production lines and workshops related to the API [1] - The successful GMP compliance check reinforces the company's commitment to leading production and quality management systems, marking a milestone for the CDMO business in extending from advanced intermediates to APIs [1]

Group 1 - Quzhou Dongfeng's controlling shareholder proposed to repurchase shares worth between 50 million to 100 million yuan for employee stock ownership plans or equity incentives [1] - Fushi Holdings' actual controller and chairman Chen Yongliang has been placed under detention by a national supervisory committee [2] - Chipone Technology's shareholder plans to reduce its stake by up to 1.95%, amounting to a maximum of 10.25 million shares due to personal funding needs [3] Group 2 - Leshan Electric reported a revenue of 3.395 billion yuan for 2025, a year-on-year increase of 6.24%, with a net profit of 23.4023 million yuan, up 3.68% [4] - Sanjia Technology plans to issue shares to its controlling shareholder to raise no more than 300 million yuan, with proceeds aimed at replenishing working capital and repaying bank loans [5] - GoerTek increased its share repurchase fund from a minimum of 500 million yuan to a range of 1 billion to 1.5 billion yuan [6] Group 3 - Hongbaoli clarified that it does not produce propylene oxide products, and its subsidiary's project is in the pre-production preparation stage [7] - Hunan Gold noted uncertainty regarding the future market price of its gold products despite recent price increases [8] - Great Wall Motors reported January sales of 90,300 vehicles, a year-on-year increase of 11.59% [9] Group 4 - Yanzhou Coal Mining announced the public transfer of 100% equity in Xintai Coal at a base price of 670 million yuan, which may significantly impact its net profit for 2026 [10] - Jerry Holdings signed a sales contract worth approximately 1.826 billion yuan with a U.S. client, representing 9.47% of its audited revenue for 2024 [11] - Fulongma pre-bid for four sanitation service projects in January, with a total first-year service fee of 83.5364 million yuan [12] Group 5 - China Unicom and China Telecom announced adjustments to the VAT applicable to their telecom services, which will affect their revenue and profits starting January 1, 2026 [13][17] - BAIC Blue Valley reported January sales of 8,073 vehicles, a year-on-year increase of 11.83% [19] - Penghui Energy submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [20] Group 6 - Haichuang Pharmaceutical passed the GMP compliance inspection for its soft capsule production line [21] - BGI Intelligent Manufacturing plans to acquire 100% equity in two companies for a total of 365.7 million yuan, aiming to integrate advanced technology platforms [22] - Jiamei Packaging's stock resumed trading after a suspension for volatility investigation [23] - Fenglong Co. also resumed trading following the completion of its stock trading suspension investigation [24]

Core Viewpoint - The announcement by Tuoxin Pharmaceutical indicates that its subsidiary, Xinxiang Pharmaceutical, has successfully passed the GMP compliance inspections for its production facilities related to the active pharmaceutical ingredients (APIs) Olaparib and Cytidine. This compliance is expected to enhance product quality stability and production capacity, thereby supporting future business expansion [1]. Group 1: GMP Compliance - Xinxiang Pharmaceutical received two GMP compliance inspection notices from the Henan Provincial Drug Administration [1]. - The production lines for the APIs Olaparib (an anti-tumor drug) and Cytidine have met the relevant regulatory requirements [1]. - The successful GMP compliance will enable the company to better meet market demand for these pharmaceuticals [1]. Group 2: Market Impact - The API Cytidine is now ready for market sales, while Olaparib will be available after filing with the National Medical Products Administration due to a change of address [1]. - This compliance is expected to significantly boost the company's ability to ensure stable product quality and supply capacity [1].

Core Viewpoint - The company, Tuoxin Pharmaceutical (301089.SZ), announced that its wholly-owned subsidiary, Xinxiang Pharmaceutical Co., Ltd., has received two GMP compliance inspection notices from the Henan Provincial Drug Administration, indicating that its production facilities meet the required quality management standards for drug production [1]. Group 1: GMP Compliance - Xinxiang Pharmaceutical's facilities for the active pharmaceutical ingredients (APIs) Olaparib (an anti-tumor drug) and Cytidine Diphosphate Choline have passed the GMP compliance inspection [1]. - The approval allows the API Cytidine Diphosphate Choline to be marketed immediately, while Olaparib will be available for sale after filing with the National Medical Products Administration due to a change of address [1]. Group 2: Business Implications - The successful GMP compliance will enhance the company's ability to ensure product quality stability and production supply capacity [1]. - This development is expected to better meet market demand for the relevant drugs and significantly promote the company's future business expansion [1].

Core Viewpoint - Jianfeng Group's subsidiary, Zhejiang Jianfeng Pharmaceutical Co., has passed the GMP compliance inspection for its raw material production line of Tafluprost, ensuring the supply capability for Tafluprost eye drops and enriching the company's product line [1] Group 1 - Jianfeng Pharmaceutical has received the GMP compliance inspection result announcement from the Zhejiang Provincial Drug Administration [1] - The successful inspection allows the company to produce Tafluprost raw materials, which is critical for the manufacturing of Tafluprost eye drops [1] - This development enhances the company's product offerings and strengthens its position in the pharmaceutical market [1]

Group 1 - The company, Aorite Pharmaceutical Co., Ltd., has received a GMP compliance inspection notice from the Zhejiang Provincial Drug Administration, confirming that its production lines meet the required standards [1] - The inspection covered the production of active pharmaceutical ingredients, specifically mometasone furoate and betamethasone, conducted from November 12 to November 14, 2025 [1] - The inspection concluded that the company complies with the relevant laws and regulations, including the Drug Administration Law and the Good Manufacturing Practice (GMP) guidelines [1] Group 2 - The company is expected to maintain stable product quality and production capacity, which will help meet market demand for its pharmaceutical products [3] - The company acknowledges that future sales may be influenced by market conditions and industry policies, indicating potential uncertainties in the pharmaceutical sector [3]

Group 1 - The company, Hunan Fangsheng Pharmaceutical Co., Ltd., has received a GMP compliance inspection notice from the Hunan Provincial Drug Administration, indicating that its production lines meet the required standards [1][2]. - The inspection took place on July 8, and from July 15 to 17, 2025, focusing on the production lines for Ezetimibe and Benidipine in the raw material drug workshop [1]. - The inspection concluded that the company complies with the Drug Administration Law, the Drug Production Supervision and Administration Measures, and the Good Manufacturing Practice (GMP) standards [1][2]. Group 2 - The successful GMP compliance inspection is expected to enhance the company's ability to diversify its product offerings and maintain stable production capacity to meet market demand [2]. - The pharmaceutical industry is characterized by high technology, high risk, and high added value, which means that future sales of various products may be influenced by market conditions and industry policies, leading to significant uncertainty [2].

Core Points - The announcement details the results of GMP compliance inspections for two pharmaceutical companies in Shaanxi Province, confirming that both companies meet the required standards [1] Group 1: Company Inspections - Shaanxi Baiyun Pharmaceutical Co., Ltd. was inspected from September 9 to September 12, 2025, and was found to be compliant with GMP requirements [1] - Shaanxi Jingyang Jinlan Skin Disease Research Institute and Shaanxi Kanghui Pharmaceutical Co., Ltd. were inspected on July 22, 2025, and from July 30 to August 1, 2025, respectively, and both were also found to be compliant with GMP requirements [1]

Core Viewpoint - Beijing Tiantan Biological Products Co., Ltd. announced that its subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. has received the Drug GMP Compliance Inspection Notice and the updated Drug Production License, indicating the completion of the production site change for the product "Recombinant Human Coagulation Factor VIII" and the potential for expanded production capacity [1][4]. Group 1: GMP Compliance Inspection - Chengdu Rongsheng received the Drug GMP Compliance Inspection Notice from the Sichuan Provincial Drug Administration [1]. - The inspection was conducted from August 18 to August 21, 2025, and concluded that the company complies with the Drug Production Quality Management Standards (2010 revision) and related appendices [2]. Group 2: Drug Production License Changes - The production scope for Chengdu Rongsheng has been updated to include the production of "Recombinant Human Coagulation Factor VIII," limited to registered application use, following the successful GMP compliance inspection [3]. - The production address remains the same: No. 280, Jingyuan Road, Shuangliu District, Chengdu, Sichuan Province [3]. Group 3: Impact on the Company - The product "Recombinant Human Coagulation Factor VIII" was approved for market launch in September 2023, and the production site change was approved in July 2025 [4]. - The completion of the production site change allows for an increase in production scale for the product [4].